Key result
Polypharmacy linked to ~269% higher one-year mortality after hip fracture surgery.
Why the study?
The study aimed to investigate the impact of polypharmacy on post-operative hip fracture mortality and its correlation with Nottingham Hip Fracture Score predicted mortality.
Does polypharmacy increase 30-day and one-year mortality in hip fracture patients aged 65 years and over undergoing operative management?
Cohort (n=224)
No
Does polypharmacy increase 30-day and one-year mortality in hip fracture patients aged 65 years and over undergoing operative management?
Polypharmacy is associated with significantly higher 30-day and one-year mortality following operative management of hip fractures in patients aged 65 and older, suggesting it could be a valuable addition to risk prediction models like the NHFS.
Answers are grounded in this paper and cite their sources.
Polypharmacy flags higher post-hip fracture mortality risk; hypothesis-generating for risk models, needs prospective validation before practice change.
Introduction Hip fractures include intra- and extracapsular fractures with hip hemiarthroplasty, intramedullary (IM nailing), dynamic hip screw (DHS) fixation and cannulated cancellous screws being the main treatment options. The Nottingham Hip Fracture Score (NHFS) is used to predict the risk of 30-day mortality with some studies investigating its use for one-year mortality. This study aims to investigate the impact of polypharmacy on post-operative hip fracture mortality and the correlation with NHFS predicted mortality. Methods A retrospective single-centre analysis was carried out on hip fracture patients aged 65 years and over who underwent operative management. Primary outcome measures were 30-day and one-year mortality along with the presence of polypharmacy. Secondary outcome measures were mortality based on procedure type, NHFSs for polypharmacy and non-polypharmacy groups, number of medications, American Society of Anesthesiologists (ASA) grade, age and gender. Polypharmacy was defined as five or more long-term medications from a selected list of drug classes. Results Thirty-day mortality was 19.3% for the polypharmacy group and 2.4% for the non-polypharmacy group (P≤0.00001), while one year mortality was 50.9% for the polypharmacy group and 2.4% for the non-polypharmacy group (P≤0.00001), the NHFS was 5.16 (±1.38) on average for the polypharmacy group and 5.07 (±1.47) for the non-polypharmacy group. Thirty-day mortality was 10/116 (8.6%) for the hemiarthroplasty patients, 3/66 (4.5%) for the DHS fixation patients and 1/32 (4.5%) for the IM nailing patients. One-year mortality was 33/116 (28.4%) for the hemiarthroplasty patients, 11/66 (16.7%) for the DHS fixation patients and 4/32 (12.6%) for the IM nailing patients. Conclusion Polypharmacy correlated with a significantly higher one-year and 30-day postoperative mortality after hip fractures with the NHFS predicting no difference in mortality. This finding could assist in decision making and help facilitate discussions with patients and family members regarding post-operative mortality risks. The NHFS may also benefit from integrating polypharmacy possibly leading to more accurate risk predictions. The IM nailing and DHS fixation patients were found to have a lower 30-day and one-year mortality than the hemiarthroplasty patients.
No takes yet. Share an insight, caveat, or question.
Al-Khatib et al. (2023) conducted a cohort in Hip fracture (n=224). Polypharmacy (≥5 long-term medications) vs. Non-polypharmacy (<5 medications) was evaluated on One-year mortality (p=≤0.00001). Polypharmacy was associated with significantly higher one-year (50.9% vs 13.8%) and 30-day (19.3% vs 2.4%) mortality compared to non-polypharmacy after hip fracture surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: